GHRP-6

Vialdyne buyer fit

Overview

GHRP-6 is a synthetic hexapeptide GHSR agonist within the GHRP family. What distinguishes it from its siblings (GHRP-2, Ipamorelin, Hexarelin) is a pronounced appetite-stimulating effect that runs alongside the GH-release activity. The appetite signal traces to GHRP-6's binding profile at the GHSR sitting in the hypothalamic arcuate nucleus, native ghrelin is the body's endogenous hunger hormone, and GHSR agonists at higher doses partially recapitulate the appetite-driving activity that ghrelin natively delivers. The published research therefore covers two distinct lanes: GH-release pharmacology and orexigenic applications, making this molecule the right tool when both effects are desired and the wrong tool when either is a confounder. Vialdyne releases GHRP-6 as a lyophilised powder against a ≥99.0% main-peak HPLC specification. SPPS access to the hexapeptide is straightforward, so the standard release packet centres on peak-integration RP-HPLC plus ESI-MS identity. Catalogue strengths are 5 mg and 10 mg, sized to typical bench-scale research workflows. Selection rule: appetite-pharmacology endpoints point to GHRP-6 as the cleanest GHRP-family choice; clean GH-selective work points to Ipamorelin instead, both the appetite and cortisol-axis effects of GHRP-6 become contamination in that context.

Applications & buyer fit

GH-axis peptides ship to two main buyer types: compounding pharmacies dispensing under physician supervision, and research labs studying somatotropic-axis pharmacology. Pharmacies typically want sterile-filled vials with the full release packet (sterility, endotoxin, CCI); labs typically want loose-format lyophilized powder with sequence verification. Blends (the CJC-1295 / Ipamorelin combination is the canonical example) are usually co-lyophilized rather than solution-mixed for potency stability.

Primary buyer fit: academic and contract research laboratories.

Specifications

CAS

87616-84-0

Appearance

White to off-white lyophilized powder

Purity (HPLC)

≥ 99.0%

Strength

5 mg – 10 mg

Packaging

10 vials/box · base pack (multiples of 10)

Half-life

≈ 1.9 minutes

MOQ

On request

Lead time

10–18 days

Storage

2–8°C, protect from light

Certificate of Analysis

Representative COA previews for GHRP-6; request the certificate matched to the offered or supplied lot from sales. These are previews — request the full high-resolution certificate for any lot.

VerifiedRequest full COA →

GHRP-6

VD260428-G610083 · 99.22%

VerifiedRequest full COA →

GHRP-6

VD260428-G65082 · 99.00%

Regulatory note

Sold as a pharmaceutical-grade active for research and for compounding-pharmacy formulation where local regulations permit (notably 503A / 503B in the United States and analogous regimes elsewhere). Not a finished dosage form. Sterile-filled vials are available with full release documentation; the buyer is responsible for verifying scheduling and dispense requirements in the destination market.

Selected literature

1. Bowers CY, Momany FA, Reynolds GA, Hong A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 1984;114(5):1537-1545.
2. Bowers CY, Sartor AO, Reynolds GA, Badger TM. On the actions of the growth hormone-releasing hexapeptide, GHRP. Endocrinology. 1991;128(4):2027-2035.
3. Popovic V, Damjanovic S, Micic D, Djurovic M, Dieguez C, Casanueva FF. Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: evidence that GHRP-6 main action is exerted at the hypothalamic level. J Clin Endocrinol Metab. 1995;80(3):942-947.
4. Pandya N, DeMott-Friberg R, Bowers CY, Barkan AL, Jaffe CA. Growth hormone (GH)-releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulation. J Clin Endocrinol Metab. 1998;83(4):1186-1189.
5. Micic D, Casabiell X, Gualillo O, Pombo M, Dieguez C, Casanueva FF. Growth hormone secretagogues: the clinical future. Horm Res. 1999;51(Suppl 3):29-33.
6. Cabrales A, Gil J, Fernández E, et al. Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteers. Eur J Pharm Sci. 2013;48(1-2):40-46.

Frequently asked questions